Description: Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. It offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to dosage forms for the pharma and consumer health, and nutrition industries, as well as develops cell and gene therapies. The company also provides drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients; and agricultural products and advanced coatings and composites, as well as microbial control solutions that combat dangerous viruses, bacteria, and other pathogens. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Home Page: www.lonza.com
Muenchensteinerstrasse 38
Basel,
4002
Switzerland
Phone:
41 61 316 81 11
Officers
Name | Title |
---|---|
Dr. Wolfgang Wienand Ph.D. | Chief Executive Officer |
Mr. Philippe Deecke | Chief Financial Officer |
Ms. Maria Soler Nunez | Head of Group Operations |
Mr. Dirk Oehlers | Vice President of Investor Relations |
Mr. Andreas Bohrer | Group General Counsel & Company Secretary |
Ms. Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility |
Ms. Victoria Morgan | Head of External Communications |
Ms. Jennifer Clancy | Senior Director of Global Marketing |
Dr. Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability |
Mr. Jean-Christophe Hyvert | President of Biologics Division |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 31.6456 |
---|---|
Trailing PE: | 67.0912 |
Price-to-Book MRQ: | 4.1287 |
Price-to-Sales TTM: | 6.5272 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 17834 |